MAP2K7 and melanoma: Whether or not MEK gain-of-function mutations are present pre- or post-BRAF and/or MEK inhibition (that is, a driver or contributor to oncogenesis versus an evolved resistance mechanism) are factors that will require careful consideration and clinical planning when developing a treatment strategy for melanoma patients.